The earnings call highlighted strong revenue growth and promising developments in the O&P channel and international markets. However, the company faced challenges in lead generation due to changes in Meta's policies and high denial rates from Medicare Advantage plans, which impacted the authorization rate and operating expenses. Despite these challenges, the company maintained its full-year guidance and showed confidence in overcoming these hurdles.

Company Guidance -

Q3 2025

During Myomo's First Quarter 2025 Earnings Conference Call, the company provided several key metrics reflecting strong performance and strategic guidance despite facing some challenges. The company reported a significant year-over-year revenue growth of 162%, reaching $9.8 million, with Medicare Part B patients contributing to 60% of this revenue. It delivered 182 MyoPro units, a 100% increase compared to Q1 2024, and saw a 31% rise in the average selling price (ASP). The patient pipeline expanded by 33%, ending the quarter with nearly 1,500 patients, and 213 MyoPros were authorized and ordered. While the O&P channel revenue was $475,000, up 87% year-over-year, it reflected seasonal fluctuations. The company navigated challenges with lead generation due to changes in advertising policies by Meta, which affected lead efficiency early in the quarter, but recovered to achieve a record number of leads in April. Additionally, Myomo maintained its guidance for 2025, expecting full-year revenue to be between $50 million and $53 million, indicating growth of 54% to 66% over the previous year. The company also highlighted ongoing efforts to expand its O&P distribution channel and address insurance authorization challenges to enhance its market penetration.

Record Revenue Growth in Q1 2025

Q1 revenues increased by more than 160% to $9.8 million, driven by a 100% increase in MyoPro units delivered year-over-year and a 31% increase in average selling price.

Significant Growth in Medicare Part B Revenue

Medicare Part B patients represented 60% of revenue, highlighting strong adoption and coverage for MyoPro devices.

Expansion of O&P Channel

Training completed for over 300 CPOs, up from 160, with significant progress in becoming Certified MyoPro Centers of Excellence.

International Sales Performance

International business generated over $1.3 million, primarily from Germany, indicating strong growth in international markets.

Myomo (MYO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MYO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.09 / -	-0.03	―	―	―
Aug 11, 2025	2025 (Q2)	-0.11 / -0.11	-0.03	-266.67% (-0.08)	―
May 07, 2025	2025 (Q1)	-0.08 / -0.08	-0.1	20.00% (+0.02)	―
Mar 10, 2025	2024 (Q4)	-0.02 / -0.01	-0.07	85.71% (+0.06)	―
Nov 06, 2024	2024 (Q3)	-0.04 / -0.03	-0.06	50.00% (+0.03)	―
Aug 06, 2024	2024 (Q2)	-0.07 / -0.03	-0.04	25.00% (+0.01)
May 08, 2024	2024 (Q1)	-0.10 / -0.10	-0.11	9.09% (<+0.01)
Mar 07, 2024	2023 (Q4)	-0.06 / -0.07	-0.29	75.86% (+0.22)	―
Nov 07, 2023	2023 (Q3)	-0.09 / -0.06	-0.4	85.00% (+0.34)	―
Aug 09, 2023	2023 (Q2)	-0.03 / -0.04	-0.42	90.48% (+0.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MYO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$1.76	$1.08	-38.64%
May 07, 2025	$4.84	$3.36	-30.58%
Mar 10, 2025	$4.17	$5.87	+40.77%
Nov 06, 2024	$4.18	$5.02	+20.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.